Using engineered blood stem cells to replace brain microglia in Krabbe disease
Microglia replacement using engineered HSCs for treatment of leukodystrophies
This project uses a patient's own modified blood stem cells to create healthy brain immune cells for children with Krabbe disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11320773 on NIH RePORTER |
What this research studies
You or your child would have blood stem cells taken and genetically fixed so they can make the missing GALC enzyme and become healthy brain microglia. The team will test ways to get those engineered cells into the brain after either a transplant or direct brain delivery, starting with lab and animal work to optimize engraftment. The approach is designed to avoid the need for a matched donor and to reduce transplant complications like graft-versus-host disease. Research at the University of Pennsylvania combines microglia biology and gene-modified stem-cell expertise to move this toward treatments for children with globoid cell leukodystrophy (Krabbe).
Who could benefit from this research
Good fit: Ideal candidates are infants or young children diagnosed with globoid cell leukodystrophy (Krabbe) who are eligible for hematopoietic stem cell–based or gene-modified cell therapies.
Not a fit: Children with advanced, irreversible brain damage, people without GALC mutations, or those who cannot undergo stem-cell procedures are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could deliver the missing GALC enzyme throughout the brain, slow or stop neurological decline, and reduce reliance on donor transplants.
How similar studies have performed: Allogeneic stem-cell transplants have provided partial benefit in early Krabbe patients and gene-modified HSC therapies show promise in related leukodystrophies, but enhanced microglia replacement is still experimental.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Bennett, Frederick — University of Pennsylvania
- Study coordinator: Bennett, Frederick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.